Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 2,187 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,187 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $9.87, for a total value of $21,585.69. Following the sale, the insider now owns 97,012 shares in the company, valued at approximately $957,508.44. This represents a 2.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $10.09 on Friday. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.39 and a 52-week high of $16.88. The stock’s 50-day simple moving average is $10.98 and its two-hundred day simple moving average is $11.93.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.04. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its position in shares of KalVista Pharmaceuticals by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after buying an additional 944 shares in the last quarter. HighVista Strategies LLC lifted its holdings in KalVista Pharmaceuticals by 4.5% during the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,432 shares in the last quarter. ClariVest Asset Management LLC boosted its position in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after purchasing an additional 1,535 shares during the period. Nicholas Investment Partners LP increased its stake in shares of KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after purchasing an additional 1,714 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of KalVista Pharmaceuticals during the 2nd quarter valued at $25,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).